Failure to Thrive

Overview

Failure to thrive (FTT) is a sign, not a diagnosis. It indicates inadequate growth compared to peers — a signal that the child's energy balance, metabolic homeostasis, or psychosocial environment is failing to support normal somatic growth. The modern UK term is faltering growth, adopted by NICE (NG75, 2017) to reduce stigma and shift clinical emphasis toward early identification and intervention rather than labelling. FTT demands the same systematic rigour as any other paediatric presentation: a structured history, accurate anthropometry plotted on validated growth charts, targeted (not blanket) investigation, and a coordinated multidisciplinary response. ^[1]

^{[1] [15] [19]}

The clinical importance of FTT is threefold. First, growth in the first 1000 days (conception to age 2) reflects and drives brain development — early growth faltering correlates with long-term cognitive, behavioural, and academic deficits that may be irreversible. Second, FTT is frequently the presenting feature of serious underlying organic disease — coeliac disease, cystic fibrosis, congenital heart disease, and inborn errors of metabolism may all declare themselves first as poor weight gain. Third, non-organic FTT is a sentinel marker of psychosocial adversity — poverty, food insecurity, parental mental illness, and neglect — and may be the child's only route to safeguarding protection. ^[1]

Definition and Classification

Enlarge

There is no single universally accepted definition. Older operational criteria combined an absolute threshold with a dynamic (trajectory) component — weight or weight-for-length persistently below the 5th percentile, or a fall across two or more percentile lines — but these centile-based criteria are now considered imprecise and hard to track over time. ^[1]

• Weight below the 2nd centile for age and sex (UK threshold, NICE: whatever the birthweight) or, classically, below the 3rd centile ^[23]
• Weight-for-length/height z-score below -2 (moderate malnutrition) or below -3 (severe)
• Falling across centile spaces on a validated growth chart over time (thresholds below)
• Weight-gain velocity below a -2 z-score for age in children under 2 years (2.3rd centile)
• BMI below the 2nd centile (may reflect undernutrition or a small build); below the 0.4th centile suggests probable undernutrition needing assessment and intervention ^[23]

The AAP/NASPGHAN 2026 clinical practice guideline renames the entity faltering weight and uses z-score cutoffs: (1) weight-for-length or BMI-for-age below -1.65 z (5th centile); (2) in children under 2 years, weight-gain velocity below -2 z (2.3rd centile); or (3) decline in weight, weight-for-length, or BMI of 1 z-score or more. ^[15]

NICE (NG75) thresholds for concern: a fall across 1 or more weight centile spaces if birthweight was below the 9th centile; 2 or more spaces if birthweight was between the 9th and 91st centiles; 3 or more spaces if birthweight was above the 91st centile; or current weight below the 2nd centile, whatever the birthweight (a centile space is the gap between adjacent centile lines on UK-WHO charts). These thresholds are adjusted for normal postnatal weight loss and physiological "catch-down." ^[23]

The organic/non-organic distinction is conceptually useful but increasingly questioned: many children have both (e.g., a child with cerebral palsy whose oromotor impairment is compounded by parental depression). The modern approach treats the categories as overlapping, not mutually exclusive, and investigates all children with persistent faltering growth rather than assuming non-organic aetiology by default. ^[1]

A second classification divides FTT by growth pattern: ^[1]

Epidemiology

FTT is reported in 5-10% of children in primary care settings (and in 3-5% of children in hospital settings, US data) and is among the most common reasons for paediatric outpatient referral; the AFP review puts it at up to 1 in 10 children. Risk factors cluster around socioeconomic deprivation: low socioeconomic status, refugee families, and developmental delay carry the clearest association, with low birth weight, fetal growth restriction, gastrointestinal disorders, congenital disorders, and chronic infection (HIV, tuberculosis) also implicated. NICE additionally flags preterm birth, neurodevelopmental concerns, and maternal postnatal depression or anxiety as associated factors. Premature and low-birthweight infants are over-represented. Recurrence within families is common, reflecting both shared environment and, in some cases, inherited metabolic or genetic conditions. ^{[1] [19] [23]}

Growth Physiology and Hormone Control

Understanding why children grow — and the endocrine orchestra that drives it — is essential to interpreting growth failure. Growth is not a single process but the net result of cellular proliferation and hypertrophy, governed by nutrition, hormones, and the genetic programme of the epiphyseal growth plate. ^[3]

The epiphyseal growth plate

Longitudinal bone growth occurs at the physis (epiphyseal growth plate), a cartilaginous structure between the epiphysis and metaphysis. Resting chondrocytes in the plate proliferate, hypertrophy, and are replaced by bone on the metaphyseal side in an orderly sequence. Growth ceases at puberty when sex steroids drive chondrocyte senescence and epiphyseal fusion. Any insult that reduces chondrocyte proliferation — undernutrition, chronic illness, cortisol excess, hypothyroidism — slows linear growth and, if sustained, causes permanent short stature. ^[3]

The growth hormone — IGF-1 axis

Growth hormone (GH), secreted by the somatotrophs of the anterior pituitary under GHRH stimulation and somatostatin inhibition, is the master regulator of postnatal linear growth. GH acts through its receptor to stimulate the liver to produce insulin-like growth factor-1 (IGF-1, somatomedin C), which mediates most of the growth-promoting effects at the growth plate. GH also has direct anabolic and lipolytic actions. ^[9]

Key points for exams:

• GH is secreted in pulsatile fashion — in children, GH pulses occur after sleep onset in association with slow-wave sleep; random GH levels are unhelpful precisely because secretion is pulsatile ^{[33] [28]}
• IGF-1 is the downstream effector; serum IGF-1 is a useful surrogate for GH action (low in GH deficiency, malnutrition, and chronic illness)
• IGFBP-3 (IGF-binding protein-3) is GH-dependent and used alongside IGF-1 as a screening test ^[9]
• GH stimulation testing (insulin tolerance test, glucagon, clonidine) confirms deficiency — but the measured GH concentration varies significantly with the stimulation test and assay used ^[9]

Thyroid hormone

Thyroxine (T4) is essential for postnatal linear growth and brain development. Congenital hypothyroidism untreated causes severe stunting and intellectual disability (cretinism); acquired hypothyroidism causes growth deceleration with delayed bone age, constipation, lethargy, and delayed puberty. This is why newborn screening for congenital hypothyroidism is universal, with immediate levothyroxine and lifelong monitoring. ^[8]

Insulin

Insulin is a major anabolic and growth-promoting hormone. Insulin deficiency (type 1 diabetes — destructive beta-cell lesions) causes thirst, polyuria, and weight loss despite polyphagia — a classic FTT pattern that can progress to ketoacidosis. Foetal hyperinsulinaemia (infant of diabetic mother) causes macrosomia; conversely, chronic undernutrition causes hypoinsulinaemia and catabolism. ^[7]

Gonadal steroids at puberty

At puberty, oestrogen (from ovaries, and from aromatisation of adrenal and testicular androgens) drives the pubertal growth spurt and then epiphyseal fusion — in both sexes, oestrogen is accepted as the critical hormone controlling growth-plate acceleration and fusion, and the pubertal spurt contributes about 20% of final adult height. The paradox: oestrogen both accelerates growth (spurt) and terminates it (fusion). In precocious puberty, early oestrogen exposure causes initial tall stature followed by premature fusion and final short stature. ^[32]

Nutrition and interpretation of the GH-IGF-1 axis

Critically, nutrition matters when interpreting the GH-IGF-1 axis: IGF-1 and IGFBP-3 are adjunct biochemical markers whose interpretation is context-dependent, and a starved or chronically ill child can biochemically mimic GH deficiency (IGF-1 is low) — interpret a low IGF-1 in nutritional context before attributing it to GH deficiency. It is also why refeeding must be cautious (refeeding syndrome, discussed below). ^[9]

Summary of hormonal control

Causes by Category

A four-part pathophysiological framework (the "A-I-R-L" approach) organises virtually every cause: Adequate intake? Ingestion/absorption? Requirements increased? Losses increased? ^[1]

Comprehensive Differential Diagnosis by System

Gastrointestinal

Coeliac disease (pooled global seroprevalence 1.4%; biopsy-confirmed prevalence 0.7%) — autoimmune enteropathy triggered by gliadin in genetically susceptible (HLA-DQ2/DQ8) individuals. Presents with FTT, chronic diarrhoea, abdominal distension, and irritability after gluten introduction (classically in the first 2 years). Serology: total serum IgA plus IgA anti-transglutaminase 2 (TGA-IgA) is the superior combination; if total IgA is low, an IgG-based test is indicated. Diagnosis: duodenal biopsy (villous atrophy, crypt hyperplasia, intraepithelial lymphocytosis — Marsh criteria), or — if TGA-IgA is ≥10× ULN and endomysial antibodies (EMA-IgA) test positive in a second blood sample — the no-biopsy route. Treatment: lifelong strict gluten-free diet. On treatment, symptoms improve early but tTG normalises within 6-12 months in only around half of children (higher initial titres take longer), and children with negative serology at ≥12 months virtually never have persisting villous atrophy. ^{[20] [4] [21] [40]}

Cystic fibrosis (CF) — caused by mutations in the CFTR gene. Newborn screening identifies affected infants, typically through a raised immunoreactive trypsinogen level followed by CFTR genetic analysis. The Cystic Fibrosis Foundation consensus recommends that the diagnosis be established by evaluation of CFTR function with a sweat chloride test, using current mutation classifications (cftr2.org) to aid interpretation. Newborns with a high immunoreactive trypsinogen level but inconclusive CFTR functional and genetic testing are designated CF screen positive, inconclusive diagnosis (CFSPID) — a category that must not be mislabelled as CF. ^[6]

Cow's milk protein allergy (CMPA) — IgE-mediated (immediate: urticaria, vomiting, anaphylaxis) or non-IgE-mediated (delayed: eczema, bloody diarrhoea, reflux, FTT). Management (DRACMA 2023): diagnostic elimination diet of 2-4 weeks for non-IgE-mediated disease (1-2 weeks if IgE-mediated), then reintroduction to confirm — oral food challenge under medical supervision for IgE-mediated and severe non-IgE (FPIES) forms — with an extensive hydrolysate or amino acid formula and maternal dairy exclusion if breastfeeding. Older, non-evidence-based recommendations suggested a first therapeutic elimination diet of at least 6 months or until age 9-12 months; DRACMA 2023 instead directs the duration of therapeutic elimination by testing (change in sensitization, oral food challenge, or supervised home reintroduction) per local protocols. Milder non-IgE forms such as allergic proctocolitis resolve quickly on elimination, and most such infants tolerate cow's milk by their first birthday. ^{[22] [38]}

Gastro-oesophageal reflux disease (GERD) — common in infants due to immature lower oesophageal sphincter. Features: recurrent vomiting, irritability, arching, refusal to feed, haematemesis (oesophagitis), recurrent aspiration. Management: positioning, feed thickeners (Gaviscon infant), alginate; domperidone is rarely used because of QT-prolongation reports in children; PPI if oesophagitis. Uncomplicated reflux (the "happy spitter") does not need treatment. ^{[1] [37]}

Inflammatory bowel disease (IBD) — Crohn disease more than ulcerative colitis causes FTT. Older children: weight loss, diarrhoea (often bloody in UC), abdominal pain, perianal disease, growth failure (Crohn can precede GI symptoms by years), delayed puberty. Diagnosis: faecal calprotectin, endoscopy/colonoscopy with biopsy, MRI enterography. ^[1]

Short bowel syndrome — history of bowel resection (necrotising enterocolitis, gastroschisis, volvulus, atresia). Malabsorption of variable severity depending on residual bowel length and site (ileum loss worse than jejunum). Management: PN dependence transitioning to enteral adaptation, long-term monitoring for bacterial overgrowth and micronutrient deficiency. ^[1]

Hirschsprung disease — congenital absence of enteric ganglion cells (aganglionosis). Chronic constipation since birth, abdominal distension, bilious vomiting, FTT. Diagnosis: rectal suction biopsy (absent ganglion cells, hypertrophied nerve trunks). Complication: enterocolitis (toxic, life-threatening). Treatment: surgical (pull-through procedure). ^[1]

Helicobacter pylori — chronic gastritis causing anorexia and occult blood loss; consider in recurrent abdominal pain with iron deficiency. ^[1]

Cardiac

Congenital heart disease (CHD) with heart failure — growth failure and malnutrition are common in infants with CHD. The mechanism is multifactorial: altered metabolic demands, compromised blood flow to the intestine leading to nutrient malabsorption, cellular hypoxia, inadequate energy intake, and poor oral-motor skills. Nutritional support in this group spans energy needs, nutrient requirements, enteral nutrition and feeding practice, guided by the infant's cardiorespiratory physiology and nutritional status. ^[5]

Respiratory

Cystic fibrosis (discussed above — the most important respiratory cause of FTT). Bronchopulmonary dysplasia (BPD) in premature infants causes increased work of breathing and calorie expenditure. Severe asthma (chronic under-treated) and bronchiectasis (post-infective, e.g., after adenovirus or pertussis) cause FTT via chronic inflammation and steroid side effects. ^[1]

Endocrine

Hypothyroidism — an important endocrine cause of growth faltering. The European Society for Paediatric Endocrinology consensus recommends worldwide neonatal screening, immediate initiation of appropriate levothyroxine (L-T4) supplementation with frequent monitoring and dose adjustment to keep thyroid hormone levels in the target ranges, assessment of the cause and severity of the disorder, and regular review of developmental and neurosensory function — monitoring continues throughout life, particularly in early childhood. ^[8]

Growth hormone deficiency (GHD) — a rare but important cause of short stature in childhood, with a prevalence of about 1 in 4000. Diagnosis rests on auxology supported by biochemical and neuroradiological evidence: GH stimulation tests remain central, but the measured GH concentration varies significantly with the stimulation test and assay used, so adjunct markers IGF-I and IGFBP-3 are used alongside. Treatment is recombinant GH, but there is no consensus on the best mechanism for determining the starting dose — weight-based and prediction-based models are both used, with dose adjustment by auxology or IGF-I targeting. Many children with isolated GHD re-test normal at the end of growth, so the diagnosis should be reassessed in poor responders. ^[9]

Cushing syndrome — exogenous steroids (most common in children — asthma, nephrotic syndrome, IBD treatment) cause growth arrest, central obesity, moon face, buffalo hump, striae, hypertension. Endogenous (rare): adrenal adenoma/carcinoma, Cushing disease (pituitary adenoma). Mechanism: cortisol suppresses GH secretion and IGF-1, and directly inhibits chondrocyte proliferation. ^[1]

Adrenal insufficiency — fatigue, hyperpigmentation (primary — high ACTH/MSH), hypotension, hypoglycaemia, salt-craving, hyponatraemia/hyperkalaemia. Congenital adrenal hyperplasia (21-hydroxylase deficiency) presents in the neonate with salt-wasting crisis; presenting FTT in an older child raises the possibility of non-classical CAH. ^[1]

Type 1 diabetes mellitus — type 1 diabetes results from destructive lesions of pancreatic beta cells; hyperglycaemia may be asymptomatic or associated with thirst, polyuria, and weight loss, and can progress to ketoacidosis and coma. Diagnosis: a casual plasma glucose of 11.1 mmol/L (200 mg/dL) or higher falls in the diabetic range, and a single diabetic-range measurement suffices when classic symptoms coexist or HbA1c is 6.5% or higher by a standardised method. ^[7]

Renal

Chronic kidney disease (CKD) — poor growth from anorexia, metabolic acidosis, renal osteodystrophy, electrolyte disturbance, growth hormone resistance (uraemic), and anaemia (low erythropoietin). Features: pallor, lethargy, oedema, hypertension, delayed puberty. Diagnosis: U&E, creatinine, eGFR, bicarbonate, phosphate, PTH, renal ultrasound. Management: phosphate binders, bicarbonate, active vitamin D (alfacalcidol), erythropoietin, growth hormone, and ultimately renal replacement therapy. ^[1]

Renal tubular acidosis (RTA) — distal RTA is defined as hyperchloraemic, non-anion-gap metabolic acidosis with impaired urinary acid excretion despite a normal or only moderately reduced GFR; the urine pH is typically above 5.5 in the face of systemic acidosis. In children the phenotype is stunted growth with bone abnormalities, together with nephrocalcinosis and nephrolithiasis driven by hypercalciuria, hypocitraturia, and relatively alkaline urine; hypokalaemia causes muscle weakness and requires continued treatment alongside alkali-based therapy. ^[13]

Nephrogenic diabetes insipidus — polyuria, polydipsia, FTT from water loss and caloric dilution. Diagnosis: water deprivation test (failure to concentrate urine), desmopressin non-response (nephrogenic). ^[1]

Infectious

Tuberculosis — chronic cough, night sweats, weight loss, fever, lymphadenopathy; consider in high-prevalence populations and contact tracing. HIV — recurrent infections, chronic diarrhoea, FTT, lymphadenopathy, oral candidiasis; vertical transmission. Intestinal parasitism — giardiasis (malabsorption), hookworm (iron deficiency anaemia), ascariasis. Recurrent UTI — occult, may present only as FTT; urine MC&S essential. Chronic hepatitis — hepatosplenomegaly, jaundice. ^[1]

Genetic and Metabolic

Down syndrome (trisomy 21) — hypotonia, brachycephaly, epicanthal folds, single palmar crease, congenital heart disease (VSD and atrioventricular septal defect), duodenal atresia, hypothyroidism — all contribute to growth restriction. Growth charts specific to Down syndrome exist. Turner syndrome (45,X) — short stature (SHOX haploinsufficiency; affects 25-50 per 100,000 females), webbed neck, shield chest, coarctation, delayed puberty; treated with GH. Prader-Willi syndrome (15q11-q13 deletion, typically paternal, or maternal uniparental disomy) — neonatal hypotonia and poor feeding, later hyperphagia and obesity, short stature, intellectual disability, hypogonadism. Russell-Silver syndrome — intrauterine and postnatal growth restriction, asymmetry, triangular face. Noonan syndrome — short stature, webbed neck, pulmonary stenosis, characteristic facies. ^{[36] [34] [41] [35] [1]}

Inborn errors of metabolism — galactosaemia (jaundice, hepatomegaly, cataracts, FTT on lactose), phenylketonuria (untreated — microcephaly, intellectual disability, FTT), glycogen storage diseases (hepatomegaly, hypoglycaemia, hyperlipidaemia), lysosomal storage disorders (organomegaly, developmental regression). Several are detected on newborn blood spot screening (e.g., PKU, galactosaemia). ^[1]

Neurological

Cerebral palsy (CP) — oromotor dysfunction (sucking, swallowing, chewing difficulty), gastro-oesophageal reflux, constipation, and high calorie expenditure from spasticity all cause FTT. Feeding assessment by speech and language therapy is essential; many require gastrostomy feeding. Neuromuscular disease (spinal muscular atrophy, muscular dystrophy) — weakness impairs feeding and breathing; scoliosis compromises respiratory function and increases energy expenditure. ^[1]

Iatrogenic and Drug-related

Excessive fruit juice (sorbitol-induced diarrhoea, caloric dilution), restrictive diets (vegan without supplementation — B12 deficiency), medication side effects (stimulants for ADHD causing anorexia), mismanaged complementary feeding (excessive milk, delayed textures). ^[1]

Growth Chart Interpretation

Accurate growth chart interpretation is the single most important clinical skill in FTT. Without it, neither diagnosis nor monitoring is possible. ^[3]

Which chart?

In the UK, the UK-WHO growth charts (Royal College of Paediatrics and Child Health, RCPCH) are standard. They are constructed using the WHO 2006 growth standards — healthy breastfed children from 6 countries with no constraints on growth — for ages 2 weeks to 4 years, combined with UK 1990 birth data for gestations 23-42 weeks (the WHO dataset did not include preterm infants); there are no centile lines between birth and 2 weeks. UK 1990 data continue from 4 years onward. Preterm infants use UK-WHO preterm/NICM or Fenton charts. Children with specific syndromes (Down, Turner, Noonan, achondroplasia) have condition-specific charts. Use of the wrong chart is a common and serious error — always confirm age, sex, and gestation before plotting. ^{[27] [3]}

What to plot

Three parameters at every visit: weight, length/height (length under 2 years lying supine; height over 2 years standing), and head circumference (routine until age 2, or longer if concern). Plotting all three on the same chart allows pattern recognition. ^[3]

Weight velocity

Expected weight gain is fastest in early infancy and falls progressively with age — what matters clinically is the trajectory over serial measurements, not any single weight. Because traditional centile-crossing criteria can be imprecise and difficult to track over time, anthropometric z-scores are now recommended, and can be calculated from a single set of measurements to grade malnutrition severity. ^[1]

Thrive lines address velocity directly: they are extra lines on close-monitoring charts (drawn at the 5th and 95th centile for velocity) whose slope defines a cutoff for failure to thrive. Weight is plotted and joined to the previous weight 4 weeks earlier; if the child's slope is shallower than the nearest thrive line, weight gain is below the fifth centile. In US practice, the AAP 2026 guideline defines slow weight gain as velocity below a -2 z-score (2.3rd centile) for age under 2 years. ^{[16] [15]}

Height velocity

• Birth to 12 months: 23-27 cm/year (~25 cm — the fastest phase of linear growth)
• 1-2 years: 10-14 cm/year; 2-3 years: ~8 cm/year; 3-5 years: ~7 cm/year
• 5 years to puberty: 5-6 cm/year
• Puberty (peak height velocity): girls 8-12 cm/year, boys 10-14 cm/year (girls earlier ~11 years, boys later ~13 years) ^[42]

A growth velocity below the normal range for age (e.g., under 5 cm/year between 5 years and puberty) should prompt further investigation — velocity is a more sensitive measure of growth than any single height. ^[42]

Head circumference velocity

• Average 1 cm/month over the first year (~12 cm total: ~2 cm/month from 0-3 months, ~1 cm/month from 3-6 months, ~0.5 cm/month from 6-12 months)
• After 1 year: ~1 cm every 6 months until 3 years of age, then ~1 cm/year between 3 and 5 years ^[43]

A head circumference crossing centiles downward suggests chronic severe undernutrition affecting brain growth, or a primary neurological/genetic cause. ^[3]

Crossing centiles — what is normal, what is not

Infants do not grow along a single centile from birth. Three physiological patterns must be recognised: ^[3]

1. Postnatal weight loss and recovery: term infants commonly lose up to 10% of birthweight in the first week; loss usually stops by 3-4 days and most regain birth weight by 2-3 weeks (usually by 14 days). Loss >10% at any stage needs careful assessment. ^{[23] [1]}
2. Catch-down (regression to the mean): between 6 and 18 months, children exhibit catch-up or catch-down growth until they reach their genetically determined curve; infants born heavy may legitimately cross centiles downward to their genetic trajectory — a normal variant not usually requiring evaluation — and by 2 years children should track along a percentile. ^{[42] [19]}
3. Catch-up growth: after a period of growth restriction (prematurity, illness), growth velocity may exceed normal to return to the centile trajectory. ^{[19] [29]}

Pathological centile crossing: crossing more centile spaces than NICE's birthweight-adjusted thresholds (see Definition), or any downward crossing that is sustained and progressive, demands investigation. Always confirm with repeat measurement (different visit, ideally different measurer) to exclude error. ^[23]

Measurement error — the silent saboteur

Before diagnosing FTT on a single chart, exclude: different scales (calibrate regularly), clothing/shoes (weigh in minimal clothing), time of day (weigh at same time), different measurers (inter-observer variation in length is substantial), recent illness (acute gastroenteritis can drop weight transiently — re-measure after recovery). The RCPCH recommends plotting at every health visit and in any unwell child. ^[3]

Practical interpretation rules

• Weight faltering before height = recent/acute nutritional deficit
• Height affected before or equally with weight = chronic undernutrition or endocrine (GH deficiency, hypothyroidism)
• Head circumference preserved, weight and height low = non-organic / undernutrition (brain protected)
• All three low = chronic severe, congenital, or genetic
• Disproportionate (height much more affected than weight) = endocrine, skeletal dysplasia
• Velocity below normal is more sensitive than any single point measurement ^[3]

Clinical Assessment

History

A meticulous history is the highest-yield investigation. Structure it around the A-I-R-L framework. ^[1]

Feeding/dietary history:

• Breastfeeding: latch, supply, frequency, duration, maternal concerns
• Formula: type, volume per feed, frequency, preparation (over-dilution is a classic cause), total daily volume
• Weaning/complementary feeding: age introduced, textures accepted, variety, food refusal
• Mealtime behaviour: duration (prolonged, difficult mealtimes suggest trouble), refusal, grazing, distractions (TV/screens)
• Intake of milk, juice, water — excessive milk intake is a common culprit
• Supplements (vitamin D, iron) ^[1]

Pregnancy and birth:

• Gestational age, birthweight (plot on preterm chart if relevant), complications (pre-eclampsia, IUGR), mode of delivery, neonatal course (NICU, oxygen, feeding) ^[1]

Developmental history:

• Milestones — delay may indicate underlying neurological/genetic cause; regression is a red flag ^[1]

Past medical and surgical:

• Recurrent infections (chest, UTI), hospitalisations, operations, chronic illness, medications ^[1]

Family and social:

• Parental heights (calculate mid-parental height — target centile: (father height + mother height ± 13 cm for boys/girls) / 2 ± 8.5 cm), sibling growth, consanguinity, inherited conditions
• Social history is pivotal: income, housing, benefits, food insecurity, parental mental health, substance misuse, domestic violence, social support, safeguarding history ^[1]

Examination

Growth parameters: weight, length/height, head circumference, BMI — all plotted. Dysmorphic features (syndromic facies). Nutritional status: muscle wasting (deltoid, gluteal), subcutaneous fat (triceps skinfold), skin/hair changes (dry, sparse, easily pluckable hair; dry skin in hypothyroidism; dermatitis in zinc/essential fatty acid deficiency), angular stomatitis (B vitamin), koilonychia (iron). Hydration: sunken fontanelle, reduced skin turgor, dry mucosae. ^[1]

Systemic examination:

• Cardiac: murmur (CHD), tachypnoea, hepatomegaly, sweating with feeds (heart failure)
• Respiratory: wheeze, crackles, clubbing (CF, bronchiectasis), chest deformity
• Abdomen: distension (coeliac, Hirschsprung, malnutrition/kwashiorkor), hepatosplenomegaly (storage disease, infection), masses, perianal disease (IBD)
• Neurological: tone, power, reflexes (CP, neuromuscular disease), development
• Skin: bruising, scars (safeguarding), eczema (allergy), rash (systemic disease) ^[1]

Mid-parental height (target height) calculation

For a boy: (father's height + mother's height + 13 cm) / 2, ± 8.5 cm. For a girl: (father's height + mother's height − 13 cm) / 2, ± 8.5 cm. ^{[28] [23]}

This defines the child's genetic target range; growth outside this range suggests pathology. NICE adds that a length/height centile more than 2 centile spaces below the mid-parental centile suggests undernutrition or a primary growth disorder, and is one of the criteria for specialist referral. ^{[23] [28]}

Investigations — Targeted, Not Blanket

The evidence is clear: blanket screening panels in FTT are low-yield and generate false positives. NICE recommends, for a child with faltering growth: a clinical, developmental and social assessment; a detailed feeding/eating history (consider a food diary); and consider investigating only for urinary tract infection and coeliac disease (if the diet has included gluten) — with any further investigations only if indicated by the clinical assessment. Investigations beyond these are unlikely to reveal an underlying disorder in a child who appears well with no other clinical concerns; AAP/US practice similarly reserves testing for severe malnutrition, symptoms concerning for high-risk conditions, or failed initial treatment. Tests worth knowing, and when each is indicated: ^{[23] [1]}

Second-line, guided by clinical suspicion:

• Sweat test — if CF suspected (recurrent chest, steatorrhoea, meconium ileus)
• Stool — fat globules/Sudan stain (malabsorption), ova/cysts/parasites, faecal calprotectin (IBD), faecal elastase (pancreatic insufficiency — CF), faecal reducing substances (carbohydrate malabsorption)
• Echo — murmur, heart failure signs, CHD suspected
• IGF-1, IGFBP-3 then GH provocation test — GH deficiency (after excluding undernutrition — GH testing in a starved child is meaningless as IGF-1 is low from starvation)
• Karyotype / microarray / genetic panel — syndromic suspicion
• HIV test — risk factors, recurrent infection
• Chest X-ray — TB, chronic lung disease, cardiomegaly
• Barium/contrast swallow, pH/impedance study — GERD, malrotation
• Upper GI endoscopy with biopsy — coeliac (Marsh grading), IBD, eosinophilic oesophagitis
• Skull X-ray / pituitary MRI — GH deficiency (pituitary lesion)
• Bone age (X-ray left hand/wrist) — delayed in GH deficiency, hypothyroidism, constitutional delay; advanced in precocious puberty ^[4]

Enlarge

Detailed Nutritional Assessment

3-Day Food Diary Analysis

A comprehensive feeding assessment is the cornerstone of non-organic FTT evaluation. The 3-day food diary should include: ^[2]

Information required:

• All foods and drinks consumed (including snacks, supplements, snacks "stolen")
• Portion sizes (use household measures — tablespoons, cups; or, better, weigh)
• Timing of meals and snacks
• Mealtime environment (TV on? family meals? distractions?)
• Child's behaviour during meals (cooperative? refusing? tantrums? duration?)
• Parental response to food refusal (pressure to eat? giving up? alternative foods offered?)
• One weekend day included (routines differ) ^[2]

Nutritional analysis (with dietitian):

• Total caloric intake, compared against age-appropriate estimated requirements
• Protein adequacy
• Micronutrient adequacy (iron, calcium, vitamin D, zinc, B12)
• Fluid intake (adequate? excessive milk/juice displacing food?)
• Macronutrient distribution — fat should not be restricted in young children ^[1]

Common feeding problems identified by diary:

• Excessive cow's milk consumption — in a case series of toddlers with severe iron-deficiency anaemia, daily cow's milk intake surpassed 24 ounces (roughly 700 mL) in nearly every child with reported intake, and severe iron-deficiency anaemia strongly correlated with excess cow's milk consumption; management is to reduce milk intake and treat the anaemia. ^[10]
• Other patterns the diary exposes: excessive juice, grazing, prolonged mealtimes and screen distraction, delayed introduction of lumpy textures, over-diluted formula, and nutritionally inadequate restricted diets. ^[1]

Management — Principles and MDT Approach

Enlarge

The overarching principle: treat the cause when identified; in all cases, ensure adequate nutrition. Non-organic FTT does not mean the child does not have FTT — the growth failure is real and the nutritional rehabilitation is identical. The difference is the aetiology, not the seriousness. ^[2]

Core MDT team

• Paediatrician: overall coordination, medical assessment, investigations, diagnosis of organic causes
• Dietitian: nutritional assessment (food diary analysis), caloric calculation, feeding plan, supplement selection, NG/gastrostomy feeding regimen
• Health visitor: home visit, feeding observation in the home environment, parental education, safeguarding liaison, coordination with primary care
• Speech and language therapist: oromotor/feeding assessment (especially for texture aversion, swallowing difficulty, CP)
• Psychologist / CAMHS: parental mental health (postnatal depression), parent-child interaction, behavioural feeding interventions, attachment assessment
• Social worker: safeguarding assessment, family support, practical help (benefits, housing, food vouchers)
• Specialist nurse: community follow-up, weight monitoring, care coordination ^[2]

Nutritional rehabilitation plan

The goal is catch-up growth — growth above the normal rate for age so that the accumulated deficit is recovered. ^[1]

Stepwise approach: ^[2]

1. Dietary modification: growth faltering can usually be managed by the primary care physician, with a multidisciplinary team (nutritionist, psychologist, paediatric subspecialists) brought in when comorbid disease is identified or initial management fails; energy-dense foods, structured meals and snacks, and correction of excessive milk/juice intake come first
2. Enteral tube feeding: nasogastric or gastrostomy feeding when oral intake remains inadequate despite supplementation — standard practice in infants with CHD whose growth is failing, where feeding practice and nutrient requirements are planned with the cardiology team ^[5]

Calorie calculation for catch-up growth: estimate daily calories needed for appropriate growth against estimated current intake; in young infants this can be delivered by concentrating formula (calorie-dense preparations improve catch-up growth). During WHO rehabilitation feeding, most children take 150-220 kcal/kg/day on F-100. ^{[1] [26]}

In practice, titrate the prescribed intake against the child's weight-gain response. In a malnutrition treatment programme run on WHO protocols with starter F-75 and catch-up F-100 diets, average weight gain during rehabilitation was about 9 g/kg/day (WHO quotes a usual weight gain of 10-15 g/kg/day, reached after 2-4 weeks). ^{[14] [26]}

Micronutrients: the American Academy of Pediatrics recommends a minimum daily intake of 400 IU of vitamin D for all infants (including those who are exclusively breastfed), children, and adolescents, beginning soon after birth; assess and correct any specific deficiency (e.g., iron) identified on testing. ^[11]

Behavioural and family interventions

For non-organic FTT, behavioural feeding interventions are as important as calories:

• Establish regular mealtime routines (3 meals + 2-3 snacks, 20-30 minute meals, eat together)
• Remove distractions (TV, screens, toys)
• Positive reinforcement for eating; avoid pressure, coercion, or punishment for refusal
• Offer small portions of varied food; let the child self-feed where developmentally able
• Parent training to reduce mealtime conflict
• Treat parental mental illness (postnatal depression — this alone can transform feeding)
• Practical support: food vouchers, benefits advice, housing, cooking facilities ^[2]

WHO Management of Severe Acute Malnutrition (SAM)

When FTT has progressed to severe acute malnutrition, specialised inpatient management follows the WHO 10-step protocol. This applies in resource-limited settings and to severe cases worldwide (e.g., severe neglect, eating disorders, chronic disease decompensation). ^[2]

Criteria for SAM (admit to therapeutic feeding programme)

• Weight-for-height z-score below -3 (WHO 2006 standards)
• MUAC (mid-upper arm circumference) below 11.5 cm (6-59 months) — community screening cutoff under 115 mm
• Bilateral pitting oedema of nutritional origin (kwashiorkor — severe acute malnutrition with oedema)
• Children with appetite (pass the appetite test) and clinically well/alert are treated as outpatients; those with complications, severe (+++) oedema, failed appetite test, or IMCI danger signs are inpatients ^[24]
• Moderate acute malnutrition (MAM) = weight-for-height -2 to -3 Z, or MUAC 115 mm to under 125 mm ^[24]

Phase 1: Stabilisation (days 1-7) — treat the immediate threats to life ^[2]

1. Stabilise with the starter diet: WHO inpatient protocols treat children on a starter F-75 diet during initial stabilisation before catch-up feeding begins; stabilisation precedes weight gain. ^[14]

2. Avoid refeeding syndrome: screen for risk, reintroduce calories cautiously, and monitor phosphorus, potassium, and magnesium — refeeding syndrome involves a fall in these electrolytes and/or thiamin deficiency within 5 days of calorie reintroduction. ^[12]

3. Treat/prevent dehydration: use ReSoMal (reduced osmolarity oral rehydration solution for malnutrition — lower sodium, higher potassium than standard ORS). Avoid IV fluids unless in shock — malnourished children tolerate fluid poorly (heart failure risk). Rehydrate slowly: 5 mL/kg every 30 minutes for the first 2 hours, then 5-10 mL/kg per hour for the next 4-10 hours; continue breastfeeding and give 50-100 mL ReSoMal after each watery stool. ^{[26] [25]}

4. Correct electrolyte imbalance: all severely malnourished children are deficient in potassium and magnesium (correction takes about 2 weeks) and have excess total body sodium (despite often appearing hyponatraemic). F-75 is formulated low-sodium, high-potassium. Give potassium 3-4 mmol/kg/day and magnesium 0.4-0.6 mmol/kg/day. Do NOT give diuretics for oedema — the oedema is not fluid overload, and prepare food without added salt. ^[25]

5. Treat/prevent infection: assume infection even without fever and give antibiotics to all severely malnourished children — uncomplicated inpatients get oral amoxicillin for 5 days; complicated cases get benzylpenicillin 50,000 U/kg IV/IM every 6 h or ampicillin 50 mg/kg IV/IM every 6 h for 2 days, then oral amoxicillin 25-40 mg/kg every 8 h for 5 days, PLUS gentamicin 7.5 mg/kg IV/IM once daily for 7 days. Give measles vaccine if ≥6 months and unvaccinated (or vaccinated before 9 months); delay if in shock. Tuberculosis and HIV are common co-infections — screen. ^{[25] [26]}

6. Correct micronutrient deficiencies: give vitamin A on day 1 (50,000 IU if under 6 months, 100,000 IU if 6-12 months, 200,000 IU if over 12 months), repeated on days 2 and 14 only if eye signs of vitamin A deficiency or a history of measles — no high dose is needed when F-75/F-100/RUTF (WHO-specification, already containing vitamin A, zinc and copper) are used; where pre-mixed feeds are unavailable, WHO gives a 1.5% zinc acetate solution by mouth at 1 mL/kg/day. Give folic acid 5 mg on the first day then 1 mg/day. Do NOT give iron during the acute phase — wait until appetite returns and weight gain starts (usually the second week), then give elemental iron 3 mg/kg/day. ^{[25] [26] [24]}

7. Begin cautious feeding (stabilisation): F-75 (75 kcal/100 mL) — give at least 80 kcal/kg/day but no more than 100 kcal/kg/day (below 80 the child continues to deteriorate; above 100 risks serious metabolic imbalance), maintaining feed volume around 130 mL/kg/day, fed every 2, 3 or 4 hours (12, 8 or 6 feeds/24h). The goal is metabolic stabilisation, NOT weight gain. F-75 is deliberately low-calorie to avoid overwhelming metabolic capacity (refeeding syndrome). Children stabilise over 3-7 days; oedema begins to reduce, appetite returns, infection resolves. ^[26]

8. Transition carefully to rehabilitation feeding: after stabilisation, WHO protocols move to the catch-up F-100 diet (100 kcal/100 mL) for rapid weight gain — during rehabilitation most children take 150-220 kcal/kg/day. Where children with SAM have no complications, community-based therapeutic care with ready-to-use therapeutic foods treats them entirely as outpatients — an approach that substantially reduces case-fatality rates and increases coverage compared with facility-based care alone. ^{[26] [2] [14] [24]}

9. Provide sensory stimulation and emotional support: severely malnourished children are often withdrawn, apathetic, and developmentally delayed. Provide structured play, physical affection, talk, and developmental stimulation. Involve the mother/caregiver. Without this, catch-up is incomplete even when nutrition is restored. ^[26]

10. Prepare for discharge and follow-up: WHO 2013 criteria for discharge — weight-for-height/length ≥ -2 Z-score with no oedema for at least 2 weeks, OR MUAC ≥ 125 mm with no oedema for at least 2 weeks (use the same indicator that confirmed SAM); percentage weight gain should NOT be used as a discharge criterion. The child should be eating an adequate home diet and gaining weight, with deficiencies treated, infections treated, and immunisation started. Provide nutritional counselling, link to supplementary feeding, immunisation, and follow-up after discharge to prevent relapse. ^{[24] [26]}

Refeeding syndrome — pathophysiology and prevention

Refeeding syndrome is a potentially fatal metabolic complication that occurs when feeding resumes after a period of starvation or severe undernutrition. ^[2]

Pathophysiology: During starvation, insulin is low and the body catabolises fat and protein. Electrolytes (phosphate, potassium, magnesium) are depleted intracellularly but serum levels may appear normal (the deficit is masked). When carbohydrates are reintroduced, insulin surges, driving phosphate, potassium, and magnesium into cells (for glycolysis and ATP synthesis), causing acute hypophosphataemia, hypokalaemia, and hypomagnesaemia. The consequences: cellular ATP depletion, cardiac arrhythmias, respiratory failure (diaphragmatic weakness), rhabdomyolysis, seizures, confusion, fluid retention and heart failure, and Wernicke encephalopathy (thiamine depletion by carbohydrate metabolism). ^[2]

Children at highest risk: the ASPEN consensus directs clinicians to stratify risk with explicit criteria before feeding restarts — severe malnutrition, prolonged minimal intake, and low baseline phosphate/potassium/magnesium are the central paediatric risks; the full list includes chronic antacid/diuretic use and oncology patients. ^[12]

Prevention protocol (ASPEN consensus):

• Identify at-risk children with consensus risk-stratification criteria before feeding restarts
• Reintroduce calories cautiously, aware that refeeding syndrome declares itself within 5 days of calorie reintroduction
• Monitor serum phosphorus, potassium, and magnesium: diagnostic severity is graded by the fall in any of the three — 10-20% (mild), 20-30% (moderate), over 30% and/or organ dysfunction and/or thiamin deficiency (severe) ^[12]

Safeguarding Assessment Framework

Non-organic FTT may be the only presentation of child neglect — a major contributor to growth failure; child neglect or abuse should always be ruled out, and iron deficiency is the most common complication. A structured safeguarding assessment is mandatory whenever there are red flags or the FTT is unexplained after adequate assessment. ^{[19] [1]}

When to suspect safeguarding concerns

Exam application bank (NEET-PG / INICET)

One-line answer

Failure to thrive (FTT) = weight consistently below the 3rd centile or crossing 2 major centile lines downward (classic criteria; AAP 2026 uses z-scores — weight-for-length/BMI < -1.65 z, or fall ≥ 1 z). Preferred term: faltering growth. Affects up to 1 in 10 children (5-10% in primary care). Classification: organic (identifiable pathology) vs non-organic/psychosocial — inadequate caloric intake (often psychosocial) is the commonest cause. Framework: inadequate intake, malabsorption (coeliac seroprevalence ~1.4%, CF), increased requirements (CHD), increased losses (GERD). Management: MDT approach (dietitian, health visitor, paediatrician), nutritional rehabilitation.

Worked stems (answer without another resource)

Stem 1 — Classic presentation. Map symptoms to mechanism; name the first investigation and first treatment step with dose/route if drug therapy is standard. ^[1]

Stem 2 — Unstable / complicated. List red flags that force immediate resuscitation, theatre, ICU, antidote, or reperfusion — and what you do in the first 15 minutes. ^[1]

Stem 3 — Atypical group. Elderly, pregnancy, child, or immunocompromised: how presentation and thresholds change. ^[1]

Stem 4 — Differential trap. Name the three closest mimics and one discriminator for each. ^[1]

Stem 5 — Disposition. Who goes home with safety-netting, who is admitted, who needs HDU/ICU/theatre, and what follow-up is mandatory. ^[1]

Rapid viva checklist

1. Definition + classification
2. Pathophysiology chain
3. Bedside signs / criteria
4. Score with exact components (if any)
5. Emergency bundle
6. Definitive therapy with doses
7. Complications of disease and of treatment
8. Special populations
9. Guideline/trial name if classic
10. Three exam traps

Coverage self-check

If you cannot answer any stem above from this page alone, re-read the matching section — the page is intended to be self-sufficient for final-prof and NEET-PG/INICET questions on Failure to Thrive.

^[1]

Framework for assessment (UK)

Use the Assessment Framework Triangle (Children Act 1989, Working Together 2023), assessing three domains: ^[1]

1. Child's developmental needs:

• Health (growth, immunisation, illness), education, emotional and behavioural development, identity, family and social relationships, social presentation, self-care skills ^[1]

2. Parenting capacity:

• Basic care (feeding, hygiene, warmth), ensuring safety, emotional warmth, stimulation, guidance and boundaries, stability ^[1]

3. Family and environmental factors:

• Family history and functioning, wider family, housing, employment, income, family's social integration, community resources ^[1]

A deficiency in parenting capacity (especially basic care — providing adequate food) in the context of FTT, particularly with red flags, mandates safeguarding referral. ^[1]

Action pathway

1. Discuss with the named/designated safeguarding lead within the organisation
2. Information-sharing: liaise with GP, health visitor, school nurse, social care (with appropriate consent; share without consent if risk of significant harm)
3. Refer to children's social care if neglect suspected — under Section 47 (child protection enquiry) if significant harm suspected, or Section 17 (child in need) for support
4. Strategy discussion (multi-agency — social care, police, health) if Section 47
5. Child protection conference if concerns substantiated — may lead to a child protection plan or, in severe cases, removal into care (Emergency Protection Order, Care Order)
6. Admission to a "place of safety" or hospital for the diagnostic therapeutic trial (does the child grow when adequately fed in a nurturing environment?) — catch-up growth in hospital strongly supports non-organic/neglect aetiology ^[1]

The threshold for referral should be low: it is better to over-refer and be reassured than to miss ongoing neglect. Document meticulously — contemporaneous records may be needed in court. ^[1]

Psychological Assessment

Parental and child psychological factors are central to non-organic FTT and must be assessed as rigorously as organic causes. ^[1]

Parental mental health:

• Postnatal depression — screen with the Edinburgh Postnatal Depression Scale (EPDS), a 10-item self-report; maternal postnatal depression and anxiety are recognised associations of faltering growth (NICE) and impair responsive feeding and attachment — a major, reversible contributor to FTT. Positive screens need clinical assessment. ^[39]
• Anxiety, eating disorder history (maternal anorexia can distort feeding practice), substance misuse, intellectual disability, domestic violence, history of being neglected themselves (intergenerational transmission) ^[1]

Parent-child interaction / attachment:

• Observe a mealtime: is the parent attuned to the child's hunger and satiety cues? Responsive? Or controlling, intrusive, or disengaged? Disorganised or insecure attachment is common in FTT.
• Video feedback intervention (e.g., Video Interaction Guidance) improves sensitive responsiveness. ^[1]

Child factors:

• Temperament (fussy eater, easily distracted, sensory sensitivities)
• Developmental stage (toddler autonomy seeking — food refusal as control)
• Sensory processing (food texture aversion, oral hypersensitivity — common in ex-preterm, autistic spectrum)
• Underlying neurodevelopmental condition (autism, ADHD, learning disability) ^[1]

Assessment tools:

• Edinburgh Postnatal Depression Scale (mother) — 10-item self-report
• Parent-Child Relationship Assessment — observe mealtime interaction
• Home visit (health visitor) — assess food availability, cooking facilities, family dynamics, the home environment
• Ages and Stages Questionnaire (ASQ) — developmental screening
• Consider CAMHS referral for parental mental health or child behavioural feeding disorders ^[1]

Long-term Outcomes

The prognosis of FTT is critically dependent on timing, duration, cause, and adequacy of intervention. Growth in the first 1000 days (conception to age 2) is uniquely important because it overlaps with the most rapid phase of brain development. ^[1]

Non-organic FTT

• With early, adequate nutritional intervention and family support: excellent — most children catch up by school age with no long-term sequelae
• Persistent neglect without intervention: cognitive impairment — meta-analysis of primary-care-identified cases shows a deficit equivalent to 4.2 IQ points (95% CI 2-6), with a much larger effect (−0.85 SD) in clinic-referred samples — plus behavioural problems (attention, conduct), short stature persisting into adulthood, and poorer educational attainment and employment outcomes ^[18]
• Early intervention is critical — the brain growth most rapid in the first 2 years is the most vulnerable and the least recoverable ^[1]

Organic FTT

Depends entirely on the underlying condition and its treatability:

• Coeliac disease: excellent with gluten-free diet — catch-up growth complete if treated early; untreated, increased risk of lymphoma, osteoporosis, infertility
• Cystic fibrosis: transformed by CFTR modulators — in the US Cystic Fibrosis Foundation Patient Registry, median survival age rose from 38.6 years (2012) to 68.0 years (2023); growth improves with pancreatic enzyme replacement and aggressive nutrition ^[17]
• Congenital heart disease: depends on lesion and timing of repair — early complete repair normalises growth; unrepaired complex lesions carry poor prognosis
• Growth hormone deficiency: excellent with recombinant GH — near-normal final height if treated early; bone age monitoring guides duration
• Hypothyroidism: excellent with levothyroxine if detected early (newborn screening); late detection causes irreversible neurodevelopmental harm
• Inborn errors of metabolism: often guarded — depends on specific disorder and diet responsiveness
• Chronic kidney disease: growth improves with transplantation; GH therapy used ^[1]

Monitoring and follow-up

• Weighing frequency should follow age and level of concern (NICE): no more often than daily if under 1 month; weekly at 1-6 months; fortnightly at 6-12 months; monthly from 1 year — weighing more often than needed adds to parental anxiety ^[23]
• Measure length/height no more often than every 3 months while concerned ^[23]
• Growth velocity more important than single measurements — plot and review trajectory
• Head circumference should improve with nutritional rehabilitation (if it does not, suspect chronicity or primary cause)
• Developmental review at every visit — refer for early intervention services if delay identified
• Transition to adult services for chronic conditions (CF, CKD, metabolic disorders) ^[1]

Complications

Untreated or severe FTT carries significant morbidity: ^[1]

• Cognitive and neurodevelopmental impairment — the most important and potentially irreversible; severity correlates with duration and severity of undernutrition, especially in the first 2 years
• Immune compromise — malnourished children have impaired cell-mediated and humoral immunity; increased susceptibility to severe infection (pneumonia, sepsis, measles, TB) and higher case fatality
• Recurrent infections — which in turn worsen nutritional status (vicious cycle)
• Micronutrient deficiencies — iron (anaemia, developmental), zinc (dermatitis, impaired healing, diarrhoea), vitamin A (xerophthalmia, blindness), vitamin D (rickets), B12 (megaloblastic anaemia, neuropathy)
• Refeeding syndrome (see above) — iatrogenic but preventable
• Hypothermia, hypoglycaemia — in severe malnutrition
• Cardiac — bradycardia, heart failure (especially during refeeding), QT prolongation from electrolyte disturbance
• Psychosocial — attachment disorders, behavioural problems, long-term mental health sequelae ^[1]

Exam Tips and Common Pitfalls

NICE (NG75) counsels the opposite default: do not admit infants or children with faltering growth unless they are acutely unwell or there is a specific indication requiring inpatient care, such as a plan to begin tube feeding — admission for a supervised feeding trial or safeguarding assessment is reserved for selected cases. ^[23]

High-yield exam points:

• FTT/faltering growth is a descriptive term, not a diagnosis — children who do not reach their expected weight, length, or BMI for age
• The commonest cause is inadequate caloric intake, identified with a detailed feeding history and physical examination
• Anthropometric z-scores are now recommended; traditional centile-crossing criteria are imprecise and hard to track
• Testing is not blanket: reserve it for severe malnutrition, symptoms concerning for high-risk conditions, or failed initial treatment
• Coeliac serology: total serum IgA plus IgA anti-transglutaminase 2 (TGA-IgA) — the superior combination; the no-biopsy route requires TGA-IgA at least 10 times ULN plus positive endomysial antibodies on a second sample
• CF diagnosis: established by sweat chloride testing of CFTR function, triggered by newborn screening with a raised immunoreactive trypsinogen
• SAM: stabilise with F-75, rehabilitate with F-100; uncomplicated SAM is managed as an outpatient on ready-to-use therapeutic foods
• Refeeding syndrome: phosphorus, potassium, and magnesium fall within 5 days of calorie reintroduction — screen risk, feed cautiously, monitor electrolytes
• Growth faltering can usually be managed in primary care; failure to recognise and treat it in the first two years may cost adult height and cognitive potential ^{[1] [4] [6] [12] [14]}

Common pitfalls:

• Over-diagnosing FTT on a single weight (always confirm with velocity and exclude measurement error)
• Forgetting to plot head circumference
• Ordering a "blanket" investigation panel rather than targeted tests
• Missing coeliac disease because total IgA was not checked (false-negative anti-tTG in IgA deficiency)
• Over-diagnosing GH deficiency in a starved child (low IGF-1 is expected in starvation)
• Mismanaging SAM with standard ORS (should use ReSoMal) or full-strength feeds (should use F-75)
• Forgetting the refeeding syndrome risk
• Failing to recognise the safeguarding dimension of non-organic FTT ^[1]

Summary Algorithm

1. Recognise: weight below 3rd centile, crossing two centiles, or low velocity — plot accurately on UK-WHO charts
2. Confirm: repeat measurement, exclude error, assess velocity over time
3. Assess: structured history (feeding, birth, development, family, social), examination (growth parameters, dysmorphism, systems, safeguarding)
4. Investigate targeted (NICE): consider urine testing and coeliac serology (total IgA + TGA-IgA); other tests only if indicated by assessment ± second-line guided by suspicion ^[23]
5. Treat the cause if organic; nutritional rehabilitation in all cases (dietitian, energy-dense diet, supplements, NG/gastrostomy as needed)
6. MDT: paediatrician, dietitian, health visitor, SLT, psychologist, social worker
7. Safeguarding: structured assessment, refer if red flags, document
8. Severe malnutrition: WHO 10-step protocol, F-75 then F-100, prevent refeeding syndrome
9. Monitor: weigh by age/level of concern (daily if under 1 month; weekly at 1-6 months; fortnightly at 6-12 months; monthly from 1 year); plot velocity; developmental review ^[23]
10. Long-term: address psychosocial adversity, early intervention services, transition for chronic disease ^[1]

FTT, at its best managed, is one of the most rewarding problems in paediatrics — a child returned to their growth trajectory, with their cognition, immunity, and future restored. At its worst neglected, it is a cause of lifelong cognitive and physical disadvantage. The difference is early recognition, thorough assessment, and a coordinated multidisciplinary response — with safeguarding vigilance throughout. ^[1]

References43ShowHide

1. [1]Goodwin ET, Buel KL, Cantrell LD. Growth Faltering and Failure to Thrive in Children. Am Fam Physician, 2023.PMID 37327159
2. [2]Collins S, Dent N, Binns P, et al. Management of severe acute malnutrition in children. Lancet, 2006.PMID 17141707
3. [3]WHO Multicentre Growth Reference Study Group WHO Child Growth Standards based on length/height, weight and age. Acta Paediatr Suppl, 2006.PMID 16817681
4. [4]Husby S, Koletzko S, Korponay-Szabó I, et al. European Society Paediatric Gastroenterology, Hepatology and Nutrition Guidelines for Diagnosing Coeliac Disease 2020. J Pediatr Gastroenterol Nutr, 2020.PMID 31568151
5. [5]Mills KI, Kim JH, Fogg K, et al. Nutritional Considerations for the Neonate With Congenital Heart Disease. Pediatrics, 2022.PMID 36317972
6. [6]Farrell PM, White TB, Ren CL, et al. Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation. J Pediatr, 2017.PMID 28129811
7. [7]Kuzuya T, Nakagawa S, Satoh J, et al. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetes Res Clin Pract, 2002.PMID 11755481
8. [8]Léger J, Olivieri A, Donaldson M, et al. European Society for Paediatric Endocrinology consensus guidelines on screening, diagnosis, and management of congenital hypothyroidism. J Clin Endocrinol Metab, 2014.PMID 24446653
9. [9]Murray PG, Dattani MT, Clayton PE. Controversies in the diagnosis and management of growth hormone deficiency in childhood and adolescence. Arch Dis Child, 2016.PMID 26153506
10. [10]Paoletti G, Bogen DL, Ritchey AK. Severe iron-deficiency anemia still an issue in toddlers. Clin Pediatr (Phila), 2014.PMID 24990367
11. [11]Wagner CL, Greer FR; American Academy of Pediatrics Section on Breastfeeding and Committee on Nutrition. Prevention of rickets and vitamin D deficiency in infants, children, and adolescents. Pediatrics, 2008.PMID 18977996
12. [12]da Silva JSV, Seres DS, Sabino K, et al. ASPEN Consensus Recommendations for Refeeding Syndrome. Nutr Clin Pract, 2020.PMID 32115791
13. [13]Vallés PG, Batlle D. Hypokalemic Distal Renal Tubular Acidosis. Adv Chronic Kidney Dis, 2018.PMID 30139458
14. [14]Singh P, Kumar P, Rohatgi S, et al. Experience and Outcome of Children with Severe Acute Malnutrition Using Locally Prepared Therapeutic Diet. Indian J Pediatr, 2016.PMID 26153390
15. [15]Kersten HB, Goday PS, Abdelhadi R, et al. Clinical Practice Guideline for Diagnosis and Management of Faltering Weight. Pediatrics, 2026.PMID 41833317
16. [16]Cole TJ. 3-in-1 weight-monitoring chart. Lancet, 1997.PMID 8996428
17. [17]Rubin JL, McKinnon C, Pedra GG, et al. Impact of CFTR Modulators on Longitudinal Cystic Fibrosis Survival and Mortality: Review and Secondary Analysis. Pulm Ther, 2025.PMID 40646419
18. [18]Corbett SS, Drewett RF. To what extent is failure to thrive in infancy associated with poorer cognitive development? A review and meta-analysis. J Child Psychol Psychiatry, 2004.PMID 15055382
19. [19]Goh LH, How CH, Ng KH. Failure to thrive in babies and toddlers. Singapore Med J, 2016.PMID 27353148
20. [20]Singh P, Arora A, Strand TA, et al. Global prevalence of celiac disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol, 2018.PMID 29551598
21. [21]Ashton JJ, Driscoll K, Himsworth J, et al. Time to normalisation of tissue transglutaminase in paediatric coeliac disease is dependent on initial titre and half of patients will normalise within 12 months. Arch Dis Child, 2022.PMID 35228203
22. [22]Meyer R, Venter C, Bognanni A, et al. World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow's Milk Allergy (DRACMA) Guideline update - VII - Milk elimination and reintroduction. World Allergy Organ J, 2023.PMID 37546235
23. [23]National Institute for Health and Care Excellence. Faltering growth: recognition and management of faltering growth in children (NG75). NICE, 2017.Source
24. [24]World Health Organization. Guideline: updates on the management of severe acute malnutrition in infants and children. WHO, 2013.Source
25. [25]World Health Organization. Pocket book of hospital care for children: guidelines for the management of common childhood illnesses. 2nd ed. WHO, 2013.Source
26. [26]World Health Organization. Management of severe malnutrition: a manual for physicians and other senior health workers. WHO, 1999.Source
27. [27]Scientific Advisory Committee on Nutrition and Royal College of Paediatrics and Child Health. Application of WHO Growth Standards in the UK. SACN/RCPCH, 2007.Source
28. [28]Royal Children's Hospital Melbourne. Primary Care Liaison pre-referral guidelines: Short stature. RCH, 2025.Source
29. [29]Tanner JM, Davies PS. Clinical longitudinal standards for height and height velocity for North American children. J Pediatr, 1985.PMID 3875704
30. [30]Zemanick ET, Ramsey B, Sands D, et al. Sweat chloride reflects CFTR function and correlates with clinical outcomes following CFTR modulator treatment. J Cyst Fibros, 2025.PMID 39755444
31. [31]Chinese Experts Cystic Fibrosis Consensus Committee; Chinese Alliance for Rare Lung Diseases. Chinese experts consensus statement: diagnosis and treatment of cystic fibrosis (2023). Zhonghua Jie He He Hu Xi Za Zhi, 2023.PMID 36990700
32. [32]Perry RJ, Farquharson C, Ahmed SF. The role of sex steroids in controlling pubertal growth. Clin Endocrinol (Oxf), 2008.PMID 17645565
33. [33]Calvert ME, Molsberry SA, Kangarloo T, et al. Acute Sleep Disruption Does Not Diminish Pulsatile Growth Hormone Secretion in Pubertal Children. J Endocr Soc, 2022.PMID 37283961
34. [34]Gravholt CH, Andersen NH, Conway GS, et al. Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting. Eur J Endocrinol, 2017.PMID 28705803
35. [35]Gunay-Aygun M, Schwartz S, Heeger S, et al. The changing purpose of Prader-Willi syndrome clinical diagnostic criteria and proposed revised criteria. Pediatrics, 2001.PMID 11694676
36. [36]Abbag FI. Congenital heart diseases and other major anomalies in patients with Down syndrome. Saudi Med J, 2006.PMID 16501680
37. [37]Morris AD, Chen J, Lau E, et al. Domperidone-Associated QT Interval Prolongation in Non-oncologic Pediatric Patients: A Review of the Literature. Can J Hosp Pharm, 2016.PMID 27403002
38. [38]Maloney J, Nowak-Wegrzyn A. Educational clinical case series for pediatric allergy and immunology: allergic proctocolitis, food protein-induced enterocolitis syndrome and allergic eosinophilic gastroenteritis with protein-losing gastroenteropathy as manifestations of non-IgE-mediated cow's milk allergy. Pediatr Allergy Immunol, 2007.PMID 17584315
39. [39]Cox JL, Holden JM, Sagovsky R. Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale. Br J Psychiatry, 1987.PMID 3651732
40. [40]Bannister EG, Cameron DJ, Ng J, et al. Can celiac serology alone be used as a marker of duodenal mucosal recovery in children with celiac disease on a gluten-free diet? Am J Gastroenterol, 2014.PMID 25070050
41. [41]Fukami M, Seki A, Ogata T. SHOX Haploinsufficiency as a Cause of Syndromic and Nonsyndromic Short Stature. Mol Syndromol, 2016.PMID 27194967
42. [42]Barstow C, Rerucha C. Evaluation of Short and Tall Stature in Children. Am Fam Physician, 2015.PMID 26132126
43. [43]Jones SG, Karsonovich T, Samanta D. Macrocephaly. StatPearls, 2026.PMID 32809621